Molecule Removal and Ease of Use: A Comparison of Two Different Dialyzers
Chronic Kidney Disease

About this trial
This is an interventional treatment trial for Chronic Kidney Disease focused on measuring Hemodialysis, Dialysis, Renal, Dialysis, Extracorporeal, Extracorporeal Dialysis
Eligibility Criteria
Inclusion Criteria:
- Adults 18 years of age or older
- Stable hemodialysis prescription using Polyflux 210H or Polyflux 21R for at least 2 months prior to study enrollment
- Dialyzing through a native fistula or Gore-Tex graft.
- Blood access must be able to provide a blood flow rate of 400 ml/min.
Exclusion Criteria:
- Non-compliance with dialysis
- Hematocrit less than 28%
- Active Infection
Sites / Locations
- DaVita Clinical Research Facility
Arms of the Study
Arm 1
Arm 2
Other
Other
HD-C4 First, then 210H
210H First, then HD-C4
Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux HD-C4 dialyzer. Following the third treatment, the subjects will be switched to the Polyflux 210H dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux 210H dialyzer. Following the third treatment, the subjects will be switched to the Polyflux HD-C4 dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.